Blood tests for Alzheimer’s disease could reshape research and care

Regulatory approval of blood-based biomarkers for Alzheimer’s disease could change diagnosis, trial design and therapeutic development. As these tests move into the clinic, physicians must assess how best to deploy them in real-world care.